STOCK TITAN

Adial Pharmaceuticals, Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company dedicated to developing treatments for addiction and related disorders. The company's primary focus is on creating personalized therapies that address the unique needs of individuals suffering from substance abuse. Adial's flagship product, AD04, is a serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in patients with specific genetic profiles. AD04 has shown promise in reducing excessive drinking in heavy drinking patients and has been investigated in the company's ONWARD™ pivotal Phase 3 clinical trial. The active ingredient in AD04 is ondansetron, which is commonly used to prevent nausea and vomiting, and now brings potential benefits in addiction treatment.

Adial leverages its expertise in pharmacogenomics to develop therapies that are tailored to the genetic makeup of patients. This approach has the potential to revolutionize the treatment of addiction by providing more effective and safer treatment options. The company recently regained compliance with Nasdaq's listing requirements by maintaining a stockholders' equity of at least $2.5 million. Adial has also been active in forming strategic partnerships, including an agreement with Adovate, LLC, which could yield up to $83 million in milestone payments and commercial royalties.

Adial's intellectual property portfolio is robust, with multiple patents protecting the combination of its genetic diagnostics and AD04 for the treatment of AUD, Opioid Use Disorder (OUD), and other dependencies. The company's recent awards include the 2023 Best Practices Technology Innovation Leadership Award from Frost & Sullivan. Financially, Adial is in a stable position, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company's research and development expenses have been judiciously managed, ensuring that resources are effectively utilized.

Recent studies have underscored the safety and efficacy of AD04, highlighting its favorable liver safety profile compared to placebo and its potential to treat other addictive disorders like gambling and obesity. Adial has initiated new activities related to its clinical development plan, including two parallel Phase 3 clinical trials of AD04 to support its approval in the shortest timeframe possible. The company is also engaging with the FDA to refine its study designs and enhance the likelihood of regulatory success.

Adial Pharmaceuticals continues to make significant strides in its mission to develop innovative solutions for addiction treatment, offering hope to millions affected by these disorders worldwide.

Rhea-AI Summary
Adial Pharmaceuticals to participate in Fall Foliage MicroCap Rodeo Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
-
Rhea-AI Summary
Adial Pharmaceuticals announces the award of a key patent for the use of its genetic diagnostic tool in combination with its drug AD04 for the treatment of alcohol use disorder and opioid use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals receives Best Practices Technology Innovation Leadership Award in precision medicine for addiction disorders industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
Rhea-AI Summary
Pre-registration for Adial Pharmaceuticals' LinkedIn Live event discussing non-abstinence-based therapies in Alcohol Use Disorder (AUD) begins on September 28th. The event will feature industry experts Joseph Volpicelli and Jonathan Hunt-Glassman, and will be moderated by Kemp Dolliver. The webinar aims to address the current treatment landscape and the need for non-abstinence-based therapeutics. The event will take place on October 4th at 2:15 p.m. ET, with a replay available afterwards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.79%
Tags
conferences
-
Rhea-AI Summary
Adial Pharmaceuticals CEO to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
-
Rhea-AI Summary
Adial Pharmaceuticals to present at ESBRA conference on new approaches in the treatment of Alcohol Use Disorder (AUD) through precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
Rhea-AI Summary
Adial Pharmaceuticals regains compliance with Nasdaq listing rules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals reports positive feedback from regulatory meetings and significant reduction in cash burn rate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
Rhea-AI Summary
Adial Pharmaceuticals announces a 1-for-25 reverse stock split of its common stock, effective August 4, 2023. The split will reduce outstanding shares from 30.5 million to 1.2 million. The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement and attract a broader group of investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
Rhea-AI Summary
Adial Pharmaceuticals provides an update on its clinical development plan for AD04, a treatment for Alcohol Use Disorder. The company received positive feedback from regulators and plans to focus on the US market. They will conduct two Phase 3 trials to support potential approval, with a total cost of approximately $25 million. AD04 is expected to be registered with the FDA in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95%
Tags
none

FAQ

What is the current stock price of Adial Pharmaceuticals (ADIL)?

The current stock price of Adial Pharmaceuticals (ADIL) is $1.005 as of November 4, 2024.

What is the market cap of Adial Pharmaceuticals (ADIL)?

The market cap of Adial Pharmaceuticals (ADIL) is approximately 6.4M.

What is Adial Pharmaceuticals' main focus?

Adial Pharmaceuticals focuses on developing personalized treatments for addiction and related disorders, leveraging pharmacogenomics to tailor therapies to individual genetic profiles.

What is AD04?

AD04 is Adial's lead investigational new drug, a serotonin-3 receptor antagonist used to treat Alcohol Use Disorder (AUD) in heavy drinking patients with specific genetic profiles.

What recent achievements has Adial Pharmaceuticals made?

Adial has regained compliance with Nasdaq's listing requirements, formed a strategic partnership with Adovate, LLC, and received multiple patents protecting its genetic diagnostics and AD04.

How is AD04 different from other treatments for AUD?

AD04 is genetically targeted, meaning it is tailored to patients with specific genetic profiles, enhancing its effectiveness and safety compared to conventional treatments.

What financial position is Adial Pharmaceuticals currently in?

Adial is financially stable, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company is also managing its research and development expenses efficiently.

What are the potential applications of AD04 beyond AUD?

AD04 has shown potential to treat other addictive disorders such as Opioid Use Disorder (OUD), gambling, and obesity.

How has Adial Pharmaceuticals engaged with regulatory agencies?

Adial has received favorable feedback from both US and European regulators, helping to refine its clinical development plan and enhance the likelihood of regulatory success for AD04.

What recent studies have been conducted on AD04?

Recent studies have highlighted AD04's safety profile, particularly its minimal impact on liver function, and its efficacy in reducing heavy drinking in patients with specific genetic markers.

What strategic partnerships has Adial Pharmaceuticals formed?

Adial has partnered with Adovate, LLC, securing potential milestone payments and royalties, and is in discussions with other potential strategic partners to support the development and launch of AD04.

What are the next steps for Adial's clinical development plan?

Adial plans to conduct two parallel Phase 3 clinical trials of AD04 and engage with the FDA to refine study designs, aiming for regulatory approval and commercialization.

Adial Pharmaceuticals, Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

6.42M
6.41M
1.8%
4.43%
0.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHARLOTTESVILLE